

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): HANNA et al.

Appl. No.: 09/

612,914

Series Code ↑

Serial No. ↑

Filed: July 10, 2000

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER

Group Art Unit 1642

Examiner: G. Bansal

Atty. Dkt. P 275543

1991-30-0019CP4C1

M#

Client Ref

Appl. Title: RECOMBINANT ANTI-CD4
ANTIBODIES FOR HUMAN THERAPY**RECEIVED**

APR 15 2002

Date: April 11, 2002

TECH CENTER 1600/2900

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

A. ☒ NOT madeB. ☐ WithdrawnC. ☐ made herewithD. ☐ made previously

For B & C
See Required
Separate Paper
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	**minus 0	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	***minus 0	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) add			+ \$280/\$140 =	+ \$0	104/204
5. Original due Date: January 12, 2002		<input type="checkbox"/> NONE			
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo) \$110/\$55 = (2 mos) \$400/\$200 = (3 mos) \$920/\$460 = (Usable only for ≤ 2mo.OA --- 4 mos) \$1,440/\$720= (Usable only for 30 day/1mo.OA --- 5 mos) \$1,960/\$980=	+ \$920		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract			- \$0		
8. Extension Fee Attached			+ \$920		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee			+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c), add			+ \$180	+ \$0	126
or if Rule 97(d) Request add			+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r)			+ \$740/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)			x \$740/370 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)			+ \$740/370	+ \$0	1179/1279
14. Petition fee for				+ \$0	
15. TOTAL FEE ENCLOSED =				\$920	

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003 275543

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Robin L. Teskin

Reg. No. 35,030

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

Sig:

Fax: (703) 905-2500

Tel: (703) 905-2200

Atty/Sec: RLT/AF

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

HANNA et al.

Group Art Unit: 1642

Application Serial No. 09/612,914

Examiner: G. Bansal

Filed: July 10, 2000

Title: *RECOMBINANT ANTI-CD4 ANTIBODIES OR HUMAN THERAPY*

G
140
418-02



* * * * *

ELECTION REPLY

RECEIVED

APR 15 2002

TECH CENTER 1600/2900

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Restriction Requirement mailed on December 12, 2001, Applicants elect without traverse Group IV, directed to a method of treating or preventing CD4 related conditions, in claims 17-36.

As the antibody used, applicants elect a gamma 4 (mutated) isotype, in CE9y4PE, and as the condition transplant rejection. Applicants respectfully submit that upon a determination that the elected species are allowable, that related therapeutic methods should also be examined, in particular, grafts-vs.-host disease.

This Election Reply is believed to be fully responsive to the outstanding Restriction and Election of Species Requirement. If the Examiner has any questions relating to this response or any other matter he is respectfully requested to contact the undersigned.

04/12/2002 G6EBRE61 00000082 09612914

01 FC:117

920.00 OP

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 

Robin L. Teskin

Registration No. 35,030

1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2000
(703) 905-2500 Facsimile

Date: April 11, 2002

Attorney Reference: 037003-0275543

/af